BRPI0113477B8 - proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula - Google Patents

proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula

Info

Publication number
BRPI0113477B8
BRPI0113477B8 BRPI0113477A BRPI0113477B8 BR PI0113477 B8 BRPI0113477 B8 BR PI0113477B8 BR PI0113477 A BRPI0113477 A BR PI0113477A BR PI0113477 B8 BRPI0113477 B8 BR PI0113477B8
Authority
BR
Brazil
Prior art keywords
delivering
protein
membrane
glycoprotein
oligonucleotide
Prior art date
Application number
Other languages
English (en)
Inventor
C Morse Clarence
A Keesler Goerge Jr
Guo Yong
Yao Zhengbin
Original Assignee
Aventis Holdings Inc
Aventis Pharma Inc
Hmr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Holdings Inc, Aventis Pharma Inc, Hmr Pharma Inc filed Critical Aventis Holdings Inc
Priority claimed from PCT/US2001/026421 external-priority patent/WO2002018572A2/en
Publication of BR0113477A publication Critical patent/BR0113477A/pt
Publication of BRPI0113477B1 publication Critical patent/BRPI0113477B1/pt
Publication of BRPI0113477B8 publication Critical patent/BRPI0113477B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"peptídios de penetração em membranas e usos dos mesmos". a presente invenção refere-se a peptídios de penetração em membranas úteis como dispositivos de distribuição intracelular in vivo, ex vivo e in vitro para um composto de interesse. mais particularmente, a invenção envolve a identificação de peptídios de penetração em membranas que podem ser usados como veículos de proteínas para a distribuição de um composto de interesse para células, e métodos de distribuição de um composto de interesse preso aos peptídios de penetração em membranas para células.
BR0113477-9 2000-08-25 2001-08-23 proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula BRPI0113477B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
PCT/US2001/026421 WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Publications (3)

Publication Number Publication Date
BR0113477A BR0113477A (pt) 2004-04-20
BRPI0113477B1 BRPI0113477B1 (pt) 2019-10-22
BRPI0113477B8 true BRPI0113477B8 (pt) 2021-05-25

Family

ID=22853919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113477-9 BRPI0113477B8 (pt) 2000-08-25 2001-08-23 proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula

Country Status (10)

Country Link
US (2) US20030229202A1 (pt)
JP (1) JP4896356B2 (pt)
KR (1) KR100810927B1 (pt)
AR (1) AR033834A1 (pt)
BR (1) BRPI0113477B8 (pt)
DE (1) DE60133585T2 (pt)
GB (1) GB0103110D0 (pt)
IL (1) IL154589A (pt)
TW (1) TWI317737B (pt)
ZA (1) ZA200301476B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
AU2003214625A1 (en) * 2002-04-08 2003-10-27 Yeda Research And Development Co. Ltd. Histone conjugates and uses thereof
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005000403A2 (en) * 2003-05-19 2005-01-06 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
AU2004317501B2 (en) * 2004-04-13 2011-09-01 Emory University Intracellular delivery of osteoinductive proteins and peptides
CA2660661A1 (en) * 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
ATE478676T1 (de) * 2005-11-04 2010-09-15 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
EP2044108A4 (en) * 2006-07-24 2010-06-30 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
KR100843634B1 (ko) * 2006-08-03 2008-07-03 연세대학교 산학협력단 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제
EP2057195A4 (en) * 2006-08-29 2010-05-12 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE SUPPRESSION OF APOPTOSIS AND METHOD OF ADMINISTERING THE SAME
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
EP2236514B1 (en) * 2008-01-25 2013-04-03 Toagosei Co., Ltd Artificial peptide and use thereof
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US8603967B2 (en) 2009-07-29 2013-12-10 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
JP5858284B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメントとその利用
WO2011052679A1 (ja) 2009-11-02 2011-05-05 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP5808082B2 (ja) * 2010-04-30 2015-11-10 株式会社Adeka 細胞への水溶性高分子量物質の導入方法及び導入剤
JP6044032B2 (ja) * 2010-05-25 2016-12-14 国立大学法人 熊本大学 物質導入用プラズマ照射装置を用いた物質導入方法
JP5854283B2 (ja) 2010-06-04 2016-02-09 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
JP6202707B2 (ja) * 2011-10-13 2017-09-27 国立大学法人鳥取大学 新規細胞膜透過ペプチド
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US20140072961A1 (en) * 2012-07-11 2014-03-13 University of Nevada, Las Vegas Method of Genome Surgery with Paired, Permeant Endonuclease Excision
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
JP2016504047A (ja) * 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
SG10201811729PA (en) 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016136707A1 (ja) 2015-02-27 2016-09-01 学校法人常翔学園 膜透過性ペプチド鎖を有する多糖誘導体
US10501564B2 (en) 2015-02-27 2019-12-10 Josho Gakuen Educational Foundation Polymer compound which has membrane-permeable peptide in side chain
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
EP3411387A4 (en) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES AS A CELL PENETRANT
SG10202110492YA (en) 2017-06-22 2021-11-29 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
US12084521B2 (en) * 2018-02-06 2024-09-10 University Of Maryland, Baltimore TLR9 inhibitors to suppress inflammatory response to pathogens
US12503492B2 (en) 2018-12-27 2025-12-23 Industry-University Cooperation Foundation Hanyang University CRISPR-Cas-based composition for gene correction
KR102386498B1 (ko) * 2018-12-27 2022-04-15 한양대학교 산학협력단 Crispr-cas를 기반으로 하는 유전자 교정용 조성물
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3176021A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
CN110441156A (zh) * 2019-07-20 2019-11-12 大连理工大学 一种基于土体稳定状态特性测量三轴试样膜嵌入量的方法
CN114716569B (zh) * 2022-04-13 2023-11-10 浙江大学 一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用
CN116120400B (zh) * 2022-12-20 2025-10-24 浙江大学杭州国际科创中心 一种细胞穿膜肽及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6197925B1 (en) * 1991-08-22 2001-03-06 Sara Lee Corporation NF-AT polypeptides and polynucleotides
US5843643A (en) * 1992-02-21 1998-12-01 Ratner; Paul L. Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6235521B1 (en) * 1996-08-09 2001-05-22 Dnavec Research Phage bonded to a nuclear location signal
US5962415A (en) 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5929042A (en) 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
AU7022998A (en) 1997-04-28 1998-11-24 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
FR2767323B1 (fr) 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US6436628B1 (en) * 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
TR200100254T2 (tr) 1998-07-13 2001-06-21 Expression Genetics, Inc. Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
US6246558B1 (en) * 1998-08-24 2001-06-12 Leviton Manufacturing Company Circuit interrupting device with reverse wiring protection
FR2786397B1 (fr) 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
DE60026998T2 (de) * 1999-06-08 2007-04-05 Aventis Pharmaceuticals Inc. Screeningsverfahren zur änderung zirkadiane-rhythmus-eiweisse
CA2392490A1 (en) 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
JP3908425B2 (ja) * 1999-12-24 2007-04-25 アルパイン株式会社 ナビゲーション装置
CN1254234C (zh) 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
JP3686961B2 (ja) * 2000-08-04 2005-08-24 シャープ株式会社 液晶表示装置及びそれを用いた電子機器
JP2002304088A (ja) * 2001-04-09 2002-10-18 Ricoh Co Ltd 画像形成装置
EP1496927A4 (en) * 2002-01-29 2007-09-12 Aventis Pasteur ZIELIMMUNOGENE
US6877262B2 (en) * 2003-07-10 2005-04-12 Ronald Bianco Perpetual calendar
DE10341112A1 (de) * 2003-09-05 2005-03-31 Li-Li Yehhsu Behälter mit separaten Speicherkammern
EP1699492A2 (en) * 2003-12-31 2006-09-13 Sanofi Pasteur Inc. Targeted immunogens

Also Published As

Publication number Publication date
ZA200301476B (en) 2004-06-22
JP4896356B2 (ja) 2012-03-14
US7754678B2 (en) 2010-07-13
KR20030034156A (ko) 2003-05-01
TWI317737B (en) 2009-12-01
GB0103110D0 (en) 2001-03-28
US20060100134A1 (en) 2006-05-11
AR033834A1 (es) 2004-01-07
BRPI0113477B1 (pt) 2019-10-22
BR0113477A (pt) 2004-04-20
IL154589A (en) 2011-08-31
JP2004512275A (ja) 2004-04-22
DE60133585D1 (de) 2008-05-21
KR100810927B1 (ko) 2008-03-10
US20030229202A1 (en) 2003-12-11
DE60133585T2 (de) 2009-06-04

Similar Documents

Publication Publication Date Title
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
IL154589A0 (en) Membrane penetrating peptides and uses thereof
ATE312172T1 (de) Immunschützendes influenzaantigen und dessen verwendung zur impfung
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BRPI0416044A (pt) sistema e método para distribuição transdérmica
DE69329903D1 (de) Bioabbaubare polymere zur zelltransplantation
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
BR0316402A (pt) vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ES2190799T3 (es) Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR9811094A (pt) Agente terapêutico para tumores linfáticos
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
Hur et al. Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE :AVENTIS PHARMCEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE : HMR PHARMA , INC.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: ANULADA AS PUBLICACOES: COD. DO DESPACHO (25.1) PUBLICADA NAS RPI 2051 DE 27/04/2010 E 2053 DE 11/05/2010 RESPECTIVAMENTE, PARA A LEGALIZACAO DO PROCESSO.

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/00

Ipc: C07K 19/00 (2006.01), C07K 14/47 (2006.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/08/2021